EQRx receives MHRA marketing approval for sugemalimab
Therapy treats patients with metastatic non-small cell lung cancer and has completed successful phase 3 trial
Read More
Tag: sugemalimab
EQRx announces further results from phase 3 trial of sugemalimab
Study involved patients with locally advanced, unresectable stage 3 non-small cell lung cancer
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
